{
    "2021-05-18": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC",
                "features": {
                    "keywords": [
                        "Tyvyt",
                        "BLA",
                        "Accepted",
                        "FDA",
                        "NSCLC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA",
                "features": {
                    "keywords": [
                        "Sintilimab",
                        "Chemo",
                        "Application",
                        "Lung Cancer",
                        "FDA"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer",
                "features": {
                    "keywords": [
                        "FDA",
                        "Regulatory Submission",
                        "Sintilimab",
                        "Pemetrexed",
                        "Platinum Chemotherapy",
                        "Nonsquamous Non-Small Cell Lung Cancer"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}